Active substanceLevocarnitineLevocarnitine
Similar drugsTo uncover
  • Carnithen
    solution inwards 
  • Carnithen
    solution in / in 
  • Carnithen
    pills inwards 
  • L-Carnitine Rompharm
    solution w / m in / in 
  • Levocarnil®
    solution inwards 
    EVALAR, CJSC     Russia
  • Nephrocaritoneum
    solution inwards 
  • Elkar®
    solution w / m in / in 
    PIK-PHARMA, LLC     Russia
  • Elkar®
    solution inwards 
    PIK-PHARMA, LLC     Russia
  • Elkar®
    solution inwards 
    PIK-PHARMA, LLC     Russia
  • Elkar®
    granules inwards 
    PIK-PHARMA, LLC     Russia
  • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:Active substance: Levocarnitine (Carnife) -0.1 g;
    excipient: water for injection - up to 1 ml.

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.16.A.A   Amino acids and their derivatives

    A.16.A.A.01   Levocarnitine

    Pharmacodynamics:

    Elkar - means for correction of metabolic processes

    L-carnitine (a natural substance related to vitamins of group B) participates in metabolic processes as a carrier of fatty acids through the membrane of cells from the cytoplasm in the mitochondria,where these acids are oxidized (the beta-oxidation process) with the formation of a large amount of metabolic energy (in the form of ATP). L-carnitine improves the resistance of nervous tissue to damaging factors (hypoxia, trauma, intoxication, etc.), inhibits the formation of keto acids and anaerobic glycolysis, reduces the degree of lactic acidosis. The drug replenishes the alkaline reserve of blood, contributes to the restoration of autoregulation of cerebral hemodynamics and increased blood supply to the affected area, accelerates the reparative processes in the lesion and has anabolic effect.

    Pharmacokinetics:

    After iv introduction at 3 h is almost completely removed from the blood. Easily penetrates into the liver and myocardium, more slowly - into the muscles. It is excreted by the kidneys mainly in the form of acyl esters (more than 80% in 24 hours).

    Indications:

    Elkar is used as part of complex therapy for acute hypoxic conditions (acute brain hypoxia, ischemic stroke, transient ischemic attack). The drug is prescribed in acute, subacute and recovery periods of cerebral circulation disorders. Applied with discirculatory encephalopathy and various traumatic and toxic lesions of the brain, in the recovery period after surgical interventions.Elkar is indicated for primary and secondary carnitine deficiency, including in patients with chronic renal failure who are on hemodialysis; with cardiomyopathy, ischemic heart disease (angina pectoris, acute myocardial infarction, post-infarction states), hypoperfusion due to cardiogenic shock and other metabolic disturbances in the myocardium.

    Contraindications:

    Individual intolerance, pregnancy, lactation (there is currently no data on the possibility and safety of the drug during pregnancy and lactation).

    Dosing and Administration:

    Elkar injected intravenously drip slowly or struyno (2-3 min) or in / m. Before / in the introduction, the contents of the ampoule are dissolved in 100-200 ml of the solvent (0.9% sodium chloride solution or 5% dextrose (glucose) solution).

    In acute disorders of cerebral circulation, 1 g / day is prescribed for 3 days, and then 0.5 g / day for 7 days. After 10-12 days, repeated courses are possible within 3-5 days.

    With the appointment of the drug in the subacute and recovery period, with discirculatory encephalopathy and various brain lesions, carnitine deficiency, the patient is administered a solution of Elkar at the rate of 0.5-1 g / day intravenously (drip, jet) or in / m (2-3 times in day) without dilution for 3-7 days.If necessary, after 12-14 days, appoint a second course.

    Intravenous injection, slowly (2-3 min.) Appointed with secondary deficiency of carnitine in hemodialysis - 2 g once (after the procedure); with acute myocardial infarction, acute heart failure - 3-5 g / day, divided into 2-3 doses in the first 2-3 days, followed by a dose reduction of 2 times; with cardiogenic shock - 3-5 g / day, divided into 2-3 admission to the patient's exit from shock. Then they switch to the oral administration of Elkar.

    Side effects:

    There may be allergic reactions, muscle weakness (in patients with uremia). With rapid administration (80 cap / min and more), pain along the vein can occur when the rate of administration is reduced.

    Interaction:

    Glucocorticosteroids contribute to the accumulation of the drug in tissues (except the liver), other anabolics enhance the effect.

    Form release / dosage:Solution for intravenous and intramuscular injection 100 mg / ml.
    Packaging:

    For 5 ml of the drug in ampoules of colorless glass with a dot or ring fracture. 10 ampoules are placed in a packet with septa. Or 5 ampoules are placed in a contour mesh package made of a polyvinyl chloride film.Two contour packs are placed in a pack of cardboard. Each pack is application of the drug.

    Packing for hospital. For 10 or 20 contour mesh packages are placed in boxes of cardboard or in boxes of corrugated cardboard. Each instruction box contains instructions for use in an amount equal to the number of contour packagings.

    Storage conditions:In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:3 years. Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-002224/08
    Date of registration:31.03.2008
    The owner of the registration certificate:PIK-PHARMA, LLC PIK-PHARMA, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp13.10.2015
    Illustrated instructions
      Instructions
      Up